EOLS
Evolus Inc.
$5.27
+$0.05(+0.96%)
49
Overall
40
Value
54
Tech
55
Quality
Market Cap
$288.87M
Volume
569.21K
52W Range
$3.86 - $12.28
Target Price
$15.60
Company Overview
| Mkt Cap | $288.87M | Price | $5.27 |
| Volume | 569.21K | Change | +0.96% |
| P/E Ratio | -5.7 | Open | $5.22 |
| Revenue | $266.3M | Prev Close | $5.22 |
| Net Income | $-50.4M | 52W Range | $3.86 - $12.28 |
| Div Yield | N/A | Target | $15.60 |
| Overall | 49 | Value | 40 |
| Quality | 55 | Technical | 54 |
No chart data available
About Evolus Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest News
Mizuho Securities Keeps Their Buy Rating on Evolus (EOLS)
TipRanks Auto-Generated Intelligence Newsdesk•12 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EOLS | $5.27 | +1.0% | 569.21K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |